FDA 483 OBSERVATION · #42 OF 1,945 MOST-CITED

Case history records- inadequate or inadequate

FDA cited this observation 568 times across 551 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Bioresearch Monitoring568
BY FISCAL YEAR
FY202636
FY202549
FY202456
FY202349
FY202236
FY202148
FY202030
FY201961
FY201869
FY201769
FY201665

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 312.62(b)

A clinical investigator did not prepare or maintain adequate case histories — the records that document all observations and data pertinent to the investigation for each trial subject, including case report forms and supporting source documents.

Why FDA writes it — Case histories are the primary evidence that a trial subject was treated per protocol and that the reported data are real and traceable. Inadequate case histories undermine both subject-safety oversight and the integrity of the data supporting a marketing application — a core Bioresearch Monitoring finding.

HOW TO COMPLY
  • Prepare and maintain adequate and accurate case histories that record all observations and other data pertinent to the investigation for each subject.
  • Include case report forms and supporting source documents (e.g., signed consent, medical records) that allow the study to be reconstructed.
  • Ensure records are attributable, contemporaneous, legible, and retained for the required period.
  • Reconcile case report forms against source data so discrepancies are found and resolved.
WHY FIRMS GET CITED
  • Source documentation incomplete or missing, so case report form entries cannot be verified.
  • Records completed after the fact, breaking contemporaneity and traceability.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 0.7× the rate of the average FDA-cited firm (5.8% vs 7.8%), across 551 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Jan J. Ilkowski, M.D. · Poznan · Bioresearch Monitoring · 2026-09-24

Failure to prepare or maintain adequate case histories with respect to observations and data pertinent to the investigation.

Lawrence Leeman, M.D., M.P.H. · Albuquerque, New Mexico · Bioresearch Monitoring · 2026-08-28

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Robert B. Molpus, M.D. · Orlando, Florida · Bioresearch Monitoring · 2026-08-28

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Steven Zeig, MD · Hollywood, Florida · Bioresearch Monitoring · 2026-08-07

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation and informed consent.

Blake G. Simmons, OD · Colorado Springs, Colorado · Bioresearch Monitoring · 2026-07-27

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation.

Zev Wainberg, M.D. · Santa Monica, California · Bioresearch Monitoring · 2026-07-10

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

GCP discipline →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →